Infineon Multiomics
Infineon Multiomics, operating under the brand InfinityScope Bio, is a Chinese biotechnology company specializing in spatial multi-omics solutions for research and clinical applications.
Profile
Provides advanced tools for analyzing proteins and genes within intact tissue samples.
Infineon Multiomics, operating under the brand InfinityScope Bio, is a Chinese biotechnology company specializing in spatial multi-omics solutions for research and clinical applications. Founded in the early 2020s, the company focuses on integrating advanced imaging and molecular profiling technologies to enable high-resolution tissue analysis. Their product portfolio includes targeted spatial proteomics platforms like imaging mass cytometry (IMC) and multiplex immunofluorescence (mIHC), as well as spatial transcriptomics solutions such as 10x Visium and DynaSpatial.
The company serves academic researchers, pharmaceutical firms, and clinical diagnostics labs seeking to map cellular interactions in complex tissues. While financial details are not publicly disclosed, InfinityScope Bio has expanded its offerings through partnerships with technology providers like Akoya Biosciences and 10x Genomics. The company's recent moves include launching proprietary antibody panels for IMC and CODEX applications, positioning it in the competitive but rapidly growing spatial biology market.
Who buys this
- Academic research institutions studying tissue biology
- Pharmaceutical companies developing targeted therapies
- Clinical diagnostics laboratories
- Biotechnology firms specializing in spatial biology
Strengths and what to watch
Strengths
- Specialized antibody panels optimized for imaging mass cytometry applications
- Integration of multiple spatial omics technologies under one service platform
- Localized support and service network in China's growing biotech market
Watch for
- Dependence on third-party platform providers like 10x Genomics and Akoya Biosciences
- Intense competition in spatial biology from global players with deeper R&D budgets
- Unclear financial position and funding trajectory in capital-intensive omics sector
Key Information
- Founded
- 2020
Frequently Asked Questions
What is Infineon Multiomics?
Infineon Multiomics, branded as InfinityScope Bio, is a Chinese biotech firm specializing in spatial multi-omics analysis. They provide tools for protein and gene study within intact tissues, offering imaging mass cytometry, multiplex immunofluorescence, and spatial transcriptomics services to researchers and diagnostics labs. Founded in the early 2020s.
What spatial proteomics technologies does InfinityScope Bio offer?
InfinityScope Bio provides imaging mass cytometry (IMC) and multiplex immunofluorescence (mIHC) platforms for spatial proteomics. Their proprietary antibody panels are optimized for IMC applications, enabling high-resolution protein mapping in tissue samples for research and clinical diagnostics purposes.
Does InfinityScope Bio support spatial transcriptomics?
Yes, InfinityScope Bio offers spatial transcriptomics solutions including 10x Visium and DynaSpatial services. These enable gene expression analysis within tissue architecture, complementing their proteomics offerings for comprehensive multi-omics studies in academic and pharmaceutical research.
Who uses InfinityScope Bio's services?
Their customers include academic researchers studying tissue biology, pharmaceutical companies developing targeted therapies, clinical diagnostics labs, and biotech firms specializing in spatial biology. They serve China's growing biotech market with localized support.
What are InfinityScope Bio's key partnerships?
InfinityScope Bio collaborates with technology providers like Akoya Biosciences and 10x Genomics. These partnerships enhance their spatial biology offerings, though create some dependence on third-party platforms in this competitive market.
How does InfinityScope Bio compare to global spatial biology competitors?
While offering integrated multi-omics platforms, InfinityScope Bio faces competition from global players with larger R&D budgets. Their differentiation lies in China-focused services and proprietary IMC panels, but financial positioning remains unclear in this capital-intensive sector.
Sources
- www.infinityscopebio.com — Company's product offerings and technology partnerships
- www.infinityscopebio.com — Details on IMC technology platform
- www.infinityscopebio.com — Information about PhenoCycler-Fusion implementation
- www.infinityscopebio.com — 10x Visium CytAssist service details